GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (HAM:IDP) » Definitions » EBIT per Share

Biogen (HAM:IDP) EBIT per Share

: €9.81 (TTM As of Dec. 2023)
View and export this data going back to 2001. Start your Free Trial

Biogen's EBIT per Share for the three months ended in Dec. 2023 was €2.28. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €9.81.

During the past 12 months, the average EBIT per Share Growth Rate of Biogen was -36.70% per year. During the past 3 years, the average EBIT per Share Growth Rate was -23.00% per year. During the past 5 years, the average EBIT per Share Growth Rate was -17.00% per year. During the past 10 years, the average EBIT per Share Growth Rate was 1.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Biogen's EBIT per Share or its related term are showing as below:

HAM:IDP' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -71   Med: 20.3   Max: 234.6
Current: -23

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Biogen was 234.60% per year. The lowest was -71.00% per year. And the median was 20.30% per year.

HAM:IDP's 3-Year EBIT Growth Rate is ranked worse than
84.62% of 852 companies
in the Drug Manufacturers industry
Industry Median: 7.85 vs HAM:IDP: -23.00

Biogen's EBIT for the three months ended in Dec. 2023 was €333 Mil.


Biogen EBIT per Share Historical Data

The historical data trend for Biogen's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT per Share
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.12 26.86 11.82 24.82 9.72

Biogen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBIT per Share Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.28 3.22 4.80 -0.50 2.28

Biogen EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Biogen's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

EBIT per Share(A: Dec. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=1415.573/145.600
=9.72

Biogen's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

EBIT per Share(Q: Dec. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=332.963/145.900
=2.28

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €9.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen  (HAM:IDP) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.


Biogen EBIT per Share Related Terms

Thank you for viewing the detailed overview of Biogen's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (HAM:IDP) Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (HAM:IDP) Headlines

No Headlines